In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kitov Pharmceuticals (NASDAQ: KTOV), with a price target of $12.50. The company’s shares closed yesterday at $2.56.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.8% and a 41.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Kitov Pharmceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.81 and a one-year low of $1.27. Currently, Kitov Pharmceuticals has an average volume of 472.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kitov Pharma Ltd. is a development stage biopharmaceutical company, which engages in drug development. The firm offers Consensi and NT219. Consensi is intended to treat osteoarthritis pain and hyper tension simultaneously, while NT219 is a cancer therapy drug that delivers anti-tumor effects and increasing survical in various cancer models.
Read More on KTOV:
